{
    "organizations": [],
    "uuid": "6e5bcbfe8f79e313b43c9e0f3eba9464927a707d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-calithera-biosciences-says-plans-t/brief-calithera-biosciences-says-plans-to-initiate-a-global-randomized-phase-2-trial-of-cb-839-in-combination-with-cabozantinib-in-q2-of-2018-idUSFWN1PV1EK",
    "ord_in_thread": 0,
    "title": "BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "#Market News   in 4 minutes BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018 Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Calithera Biosciences Inc: \n* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon:  ",
    "published": "2018-02-06T00:17:00.000+02:00",
    "crawled": "2018-02-06T00:32:26.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "minute",
        "bioscience",
        "say",
        "plan",
        "initiate",
        "global",
        "randomized",
        "phase",
        "trial",
        "combination",
        "cabozantinib",
        "q2",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "calithera",
        "bioscience",
        "inc",
        "calithera",
        "bioscience",
        "inc",
        "plan",
        "initiate",
        "global",
        "randomized",
        "phase",
        "trial",
        "combination",
        "cabozantinib",
        "q2",
        "source",
        "text",
        "eikon"
    ]
}